5-氨基酮戊酸诱导荧光在恶性胶质瘤手术中的成本效益
Cost-effectiveness of 5-aminolevulinic acid-induced fluorescence in malignant glioma surgery.
作者信息
Slof J, Díez Valle R, Galván J
机构信息
Universidad Autónoma de Barcelona, Bellaterra, Cerdanyola del Vallès, España.
Departamento de Neurocirugía, Clínica Universidad de Navarra, Pamplona, España.
出版信息
Neurologia. 2015 Apr;30(3):163-8. doi: 10.1016/j.nrl.2013.11.002. Epub 2014 Jan 24.
OBJECTIVE
This study evaluates the cost-effectiveness of 5-aminolevulinic acid (5-ALA, Gliolan®) in patients undergoing surgery for malignant glioma, in standard clinical practice conditions in Spain.
MATERIAL AND METHODS
Cost-effectiveness ratios were determined in terms of incremental cost per complete resection (CR) and incremental cost per additional quality-adjusted life year (QALY), based on data collected in the VISIONA observational study.
RESULTS
Incremental cost with 5-ALA versus conventional surgery using white light only amounts to € 4550 per additional CR achieved and € 9021 per QALY gained. A sensitivity analysis shows these results to be robust.
CONCLUSION
Malignant glioma surgery guided by 5-ALA fluorescence entails a moderate increase in hospital costs compared to current surgical practice and can be considered a cost-effective innovation.
目的
本研究在西班牙的标准临床实践条件下，评估5-氨基乙酰丙酸（5-ALA，Gliolan®）在接受恶性胶质瘤手术患者中的成本效益。
材料与方法
基于VISIONA观察性研究收集的数据，以每例完全切除（CR）的增量成本和每增加一个质量调整生命年（QALY）的增量成本来确定成本效益比。
结果
与仅使用白光的传统手术相比，使用5-ALA的增量成本为每多实现一例CR增加4550欧元，每多获得一个QALY增加9021欧元。敏感性分析表明这些结果是稳健的。
结论
与目前的手术实践相比，5-ALA荧光引导下的恶性胶质瘤手术会使医院成本适度增加，可被视为一种具有成本效益的创新。
Zotero 插件